Case Study 2 Answers Spring 2006

Similar documents
TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

PHA Case Studies V (Answers)

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

TDM of Aminoglycoside Antibiotics

PHA 5128 Spring 2000 Final Exam

PHARMACOKINETICS SMALL GROUP II:

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA 5128 Spring 2009 First Exam (Version B)

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Name: UFID: PHA Exam 2. Spring 2013

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

PHA Final Exam Fall 2006

SHC Vancomycin Dosing Guide

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

. Although there is a little

One-Compartment Open Model: Intravenous Bolus Administration:

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

BIOPHARMACEUTICS and CLINICAL PHARMACY

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Section 5.2: Pharmacokinetic properties

General Principles of Pharmacology and Toxicology

PHARMACOKINETICS SMALL GROUP I:

Multiple IV Bolus Dose Administration

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

PHA5128 Dose Optimization II Case Study I Spring 2013

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Carboplatin Time to Drop the Curtain on the Dosing Debate

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

AMINOGLYCOSIDES TDM D O N E B Y

Assessing Renal Function: What you Didn t Know You Didn t Know

2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Pharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples

Cystatin C: A New Approach to Improve Medication Dosing

Pharmacokinetics One- compartment Open Model Lec:2

Gemcitabine + Cisplatin Regimen

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Renal function vs chemotherapy dosing

Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)

BASIC PHARMACOKINETICS

Valproate overdose: what is the role of carnitine?

Public Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Understand the physiological determinants of extent and rate of absorption

Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

Perfect Endings. Home Alone. Senior Estimate. Staying Alive. Medication Madness

PHAR 7633 Chapter 20 Non Compartmental Analysis

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

PHA Final Exam Fall 2001

ECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

TDM. Measurement techniques used to determine cyclosporine level include:

Pharmacokinetic Calculations

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

CARBOplatin (AUC5) and Etoposide 100mg/m 2 Therapy-21 day

The general Concepts of Pharmacokinetics

Effects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

Contrast-Induced Nephropathy: Evidenced Based Prevention

Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop

Drug Disposition in Obesity & Protein-Calorie Malnutrition

PHA5128 Dose Optimization II Case Study 3 Spring 2013

PPP 1. Continuation, modification, and discontinuation of a medication

PHAR 7632 Chapter 16

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Simulation of the Nonlinear PK of Gabapentin and Midazolam in. Adult and Pediatric Populations. Population Approach Group in Europe (PAGE)

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

ESTIMATION OF CREATININE CLEARANCE IN PATIENTS WITH UNSTABLE RENAL FUNCTION. Roger Jelliffe, USC School of Medicine

Are Pediatric Patients Small Adults?

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

Volume 1(3) May-June 2013 Page 351

Levocetirizine dihydrochloride

Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program

2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction

NCCP Chemotherapy Regimen. Carboplatin (AUC 2) Weekly with Radiotherapy (RT)

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

Case Studies: Renal and Urologic Impairments Workshop

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Effects of Liver Disease on Pharmacokinetics

Transcription:

Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume of distribution was found to be 305 L. Derive an equation that allows estimation of the volume of distribution based on ideal and actual body weight. Normal: IBW (60kg) 105L 1.75 L/kg Excess: EBW(110-60 = 50kg) 305-105 = 200 L 4.0 L/kg (2.3 times normal) V d = 1.75 (IBW + 2.3 EBW)=1.75 IBW + 4.0 EBW

2. Based on the Cockcroft-Gault-Equation, calculate the amount of creatinine that is produced every hour from muscle in a normal 30 year old and 75 year old male subject (body weight 70 kg) with a serum creatinine of 1 mg/dl. The Cockroft-Gault equation allows us to predict the creatinine clearance (and therefore renal function/gfr) for patients differing in age and weight. For male patients, Cl creat (140 age) weight (male) = 72 Cp creat where age is in years, weight is in kg, and Cp creat is in mg/dl. The Cl creat is then in ml/min. This is an empirical equation which works only if the age, weight, and Cp creat (or Scr) are entered in the units specified. For the 30 y.o. (140 30)(70) Cl creat = = 106.94ml/min (72)(1) Although clearance is expressed in volume-per-time, the amount of creatinine eliminated-per-time may be found using the creatinine concentration given: Creatinine cleared per hour = 60min 10dL 1L (106.94ml/ min)(1mg/dl) 1hr 1L 1000ml = 64.2 mg/hr (so in 1 day, about 1.54 g of creatinine is lost which is balanced by eating and producing 1.54 g of creatine per day)) For the 75 y.o. (140 75)(70) Cl creat = = 63.2ml/min (72)(1) Creatinine cleared per hour =

60min 10dL 1L (63.2ml/min)(1mg/dL) 1hr 1L 1000ml = 37.9 mg/hr (Remember, elderly have less muscle mass which means less creatinine production)

3. J.R., is a 65-year-old, 65kg patient with a serum creatinine of 1.0mg/dL. For several weeks he received tablets of 375 µg of digoxin per day to treat his CHF. Assume that this patient cannot take anything by mouth anymore and he must be converted to daily intravenous doses of digoxin. Calculate an intravenous dose equivalent to the 375 µg tablets he ingests daily Amount of drug absorbed = F Dose = 0.7 375µg = 262. 5µg The intravenous dose should be 262.5 250µg

4. Oxazolidinone antibiotics are a new synthetic class of antibacterial agents. The FDA recently approved Linezolid, an oxazolidinone antibiotic. Administration of this antibiotic may cause gastrointestinal distress that is eliminated when taken with food. However, the presence of food may reduce bioavailability. Given the following data, determine the absolute bioavailability of 375 mg Linezolid tablets with and without food. Does food affect bioavailability? Time [hrs] C p C p C p after i.v.[µg oral [µg/ml] food oral [µg/ml] i.v.[µg oral[µg oral after food [µg 0.000 9.375 0.000 0.000 0.200 9.007 1.222 1.024 1.838 0.122 0.102 0.600 8.315 3.017 2.550 3.464 0.848 0.715 1.000 7.676 4.156 3.542 3.198 1.434 1.218 2.000 6.284 5.270 4.574 6.980 4.713 4.058 3.000 5.145 5.154 4.535 5.715 5.212 4.554 4.000 4.212 4.596 4.086 4.679 4.875 4.311 6.000 2.824 3.296 2.967 7.036 7.892 7.053 8.000 1.893 2.253 2.039 4.716 5.548 5.006 12.000 0.850 1.020 0.927 5.487 6.545 5.932 14.000 0.570 0.684 0.622 1.421 1.704 1.548 0-14 44.534 38.893 34.498 C 14 /k e = 14-2.850 3.420 3.108 0-47.384 42.313 37.606 Calculate the k e from the terminal portion of each concentration time profiles. C ln( 12 ) C ln( 0.850 ) ln( ) ln( ) k 0.570 1.020 0.684 0.927 0.622 e 20 14 = = = 0.20hr or = 0.20hr or = 0. hr Bioavailab ility( F) = PO IV

42.313 Fasted ( F) = = 0.89 47.384 37.606 Fed ( F) = = 0.79 47.384

5. Given the data below for two prednisolone tablet formulations, are these products bioequivalent? What pharmacokinetic criteria did you use to draw this conclusion? Product A Product B Ratio (%) A/B 90% Confidence Limits 0-15 h (µg 204.5 216 94.7 91.2-98.2 min/ml) 0- (µg 212 222 95.5 88.6-102.4 min/ml) C MAX (ng/ml) 1020 1053 96.9 90.8-103.0 T MAX (h) 39.6 52.8 75.0 T 1/2 (min) 186.2 170.4 109.3 Bioequivalence is determined by the 0-15 h 0- and C MAX. The 90% confidence limits of the RATIO of product A/Product B must fall within 80-125%). From this data, you would conclude that these two tablets are bioequivalent.